New research explores why there's youth in wine
14 February, 2006 by Graeme O'NeillSpanish explorer Juan Ponce de Leon might have spared himself and his men the travails of their fruitless and ultimately fatal quest for the fountain of youth in the Caribbean in 1513 by staying at home in and quaffing the genuine article from oak barrels in his wine cellar, writes Graeme O'Neill.
New agbiotech centre to open
13 February, 2006 by Ruth BeranA new AUD$20 million agricultural biotech centre will be opened by Victorian premier Steve Bracks this Wednesday.
CogState signs $400,000 functional food deal
13 February, 2006 by Ruth BeranCogState (ASX:CGS) is to provide cognition testing services to a European food products company in a contract worth more than AUD$400,000.
Pharmaxis earns regulatory thumbs-up for Aridol
13 February, 2006 by Helen SchullerThe Australian Drug Evaluation Committee has recommended to the TGA that Sydney-based drug developer Pharmaxis' (ASX:PXS) first product, the asthma diagnostic and treatment management tool Aridol, be registered for sale in Australia.
Analytica chairman defends cash position
13 February, 2006 by Ruth BeranThe ASX has issued a 'please explain' to Brisbane-based Analytica (ASX:ALT), querying whether the company will have enough cash to last it past the next quarter.
Stirling study shows reduced weight gain in rats
09 February, 2006 by Ruth BeranA study conducted for Perth-based Stirling Products (ASX:STI) has shown that its beta agonist ST810 reduced weight gain in obese Zucker rats.
Alchemia's synthetic heparin completes pilot scale process
09 February, 2006 by Ruth BeranThe first batch of Brisbane biopharma Alchemia's (ASX:ACL) synthetic heparin has completed purification -- the final stage of the pilot scale process development -- at the US facilities of the company's manufacturing partner, The Dow Chemical Company.
Ventracor implants 50, reaches CE Mark trial enrolment target
09 February, 2006 by Helen SchullerArtificial heart company Ventracor (ASX: VCR) has implanted its 50th VentrAssist left ventricular assist device (LVAD) and has reached the enrolment target of 30 implants in its European CE Mark trial.
BRC branches into MS
08 February, 2006 by Helen SchullerThe Brain Resource Company (ASX:BRC) is to supply its services to a Schering Israel funded Multiple Sclerosis study.
CSL to enter US flu market, double vaccine capacity
08 February, 2006 by Ruth BeranBiopharmaceutical company CSL (ASX:CSL) will invest AUD$80 million in plant and equipment to double capacity at its Melbourne facility to 40 million doses per season, making it one of the largest vaccine manufacturing plants in the world.
In brief: Genesis Biomedical, Select Vaccines, Pharmaxis
06 February, 2006 by Helen SchullerSydney-based Genesis Biomedical (ASX:GBL) has closed its underwritten share offer early and oversubscribed raising AUD$2.4 million, substantially boosting its coffers -- the firm had $586,000 at the end of the quarter.
Ambri boss adds perspective to US partner's decision
06 February, 2006 by Helen SchullerSydney biosensor specialist Ambri (ASX:ABI) appeared to hit a setback last week, when the company announced that its US partner would no longer work to develop Ambri's ion-channel switch (ICS).
Psiron chair spells out business plans
06 February, 2006 by Ruth BeranPsiron (ASX:PSX) has moved to reassure shareholders of its ability to fund its business plans, in the wake of last week's resignations of the company's CEO and CFO.
Glaxo opens Australian Relenza plant
06 February, 2006 by Ruth BeranFederal health minister Tony Abbott was on hand to cut the ribbon for the first of two Relenza production lines at GlaxoSmithKline's manufacturing facilities in Boronia, Victoria, last week.
Avantogen subsidiary and US company to merge
06 February, 2006 by Ruth BeranUS-listed Innovate Oncology and a wholly-owned subsidiary of Avantogen (ASX:ACU), formerly Australian Cancer Technologies, are to merge.
